US President Trump says Regeneron (REGN) offered medication at most-favoured nation prices

Trump's comments on Regeneron offering medications at most-favored nation prices could set a precedent affecting drug pricing policy, directly impacting healthcare stocks and the biotech sector. While this likely won’t have an immediate market reaction, investors should be aware of the potential implications for regulatory environments and broader market sentiment, especially in equities and pharmaceuticals.